Andrew Raubitschek

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Olafsen Tove; Betting David; Kenanova Vania E; Salazar Felix B; Clarke Pat; Said Jonathan; Raubitschek Andrew A; Timmerman John M; Wu Anna M
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.
Numbenjapon Tontanai; Wang Jianyi; Colcher David; Schluep Thomas; Davis Mark E; Duringer Julienne; Kretzner Leo; Yen Yun; Forman Stephen J; Raubitschek Andrew
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Shibata Stephen; Raubitschek Andrew; Leong Lucille; Koczywas Marianna; Williams Lawrence; Zhan Jiping; Wong Jeffrey Y C
A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Andrew Raubitschek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Olafsen Tove; Betting David; Kenanova Vania E; Salazar Felix B; Clarke Pat; Said Jonathan; Raubitschek Andrew A; Timmerman John M; Wu Anna M
Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(9):1500-8.
2009: Numbenjapon Tontanai; Wang Jianyi; Colcher David; Schluep Thomas; Davis Mark E; Duringer Julienne; Kretzner Leo; Yen Yun; Forman Stephen J; Raubitschek Andrew
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4365-73.
2009: Shibata Stephen; Raubitschek Andrew; Leong Lucille; Koczywas Marianna; Williams Lawrence; Zhan Jiping; Wong Jeffrey Y C
A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(8):2935-41.
2008: Johnson Erik E; Lum Hillary D; Rakhmilevich Alexander L; Schmidt Brian E; Furlong Meghan; Buhtoiarov Ilia N; Hank Jacquelyn A; Raubitschek Andrew; Colcher David; Reisfeld Ralph A; Gillies Stephen D; Sondel Paul M
Intratumoral immunocytokine treatment results in enhanced antitumor effects.
Cancer immunology, immunotherapy : CII 2008;57(12):1891-902.
2008: Bartlett Derek W; Colcher David; Raubitschek Andrew A
Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.
Bioconjugate chemistry 2008;19(9):1927-37.
2008: Till Brian G; Jensen Michael C; Wang Jinjuan; Chen Eric Y; Wood Brent L; Greisman Harvey A; Qian Xiaojun; James Scott E; Raubitschek Andrew; Forman Stephen J; Gopal Ajay K; Pagel John M; Lindgren Catherine G; Greenberg Philip D; Riddell Stanley R; Press Oliver W
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Blood 2008;112(6):2261-71.
2008: Bading James R; Hörling Magnus; Williams Lawrence E; Colcher David; Raubitschek Andrew; Strand Sven E
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.
Cancer biotherapy & radiopharmaceuticals 2008;23(4):399-409.
2008: Lazovic Jelena; Jensen Michael C; Ferkassian Evette; Aguilar Brenda; Raubitschek Andrew; Jacobs Russell E
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3832-9.
2008: Yazaki Paul J; Kassa Thewodros; Cheung Chia-wei; Crow Desiree M; Sherman Mark A; Bading James R; Anderson Anne-Line J; Colcher David; Raubitschek Andrew
Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.
Nuclear medicine and biology 2008;35(2):151-8.
2008: Krishnan Amrita; Nademanee Auayporn; Fung Henry C; Raubitschek Andrew A; Molina Arturo; Yamauchi Dave; Rodriguez Roberto; Spielberger Ricardo T; Falk Peter; Palmer Joycelynne M; Forman Stephen J
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):90-5.
2008: Li Lin; Bading James; Yazaki Paul J; Ahuja Amitkumar H; Crow Desiree; Colcher David; Williams Lawrence E; Wong Jeffrey Y C; Raubitschek Andrew; Shively John E
A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.
Bioconjugate chemistry 2008;19(1):89-96.
2007: Wang Jinjuan; Jensen Michael; Lin Yukang; Sui Xingwei; Chen Eric; Lindgren Catherine G; Till Brian; Raubitschek Andrew; Forman Stephen J; Qian Xiaojun; James Scott; Greenberg Philip; Riddell Stanley; Press Oliver W
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Human gene therapy 2007;18(8):712-25.
2007: Olafsen Tove; Gu Zhennan; Sherman Mark A; Leyton Jeffrey V; Witkosky Michael E; Shively John E; Raubitschek Andrew A; Morrison Sherie L; Wu Anna M; Reiter Robert E
Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):396-405.
2007: Singh Harjeet; Serrano Lisa Marie; Pfeiffer Timothy; Olivares Simon; McNamara George; Smith David D; Al-Kadhimi Zaid; Forman Stephen J; Gillies Stephen D; Jensen Michael C; Colcher David; Raubitschek Andrew; Cooper Laurence J N
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
Cancer research 2007;67(6):2872-80.
2007: Kenanova Vania; Olafsen Tove; Williams Lawrence E; Ruel Nora H; Longmate Jeffrey; Yazaki Paul J; Shively John E; Colcher David; Raubitschek Andrew A; Wu Anna M
Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
Cancer research 2007;67(2):718-26.
2006: Mamelak Adam N; Rosenfeld Steven; Bucholz Richard; Raubitschek Andrew; Nabors L Burt; Fiveash John B; Shen Sui; Khazaeli M B; Colcher David; Liu An; Osman Medhat; Guthrie Bart; Schade-Bijur Susan; Hablitz Diana M; Alvarez Vernon L; Gonda Matthew A
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3644-50.
2006: Wong Jeffrey Y C; Chu David Z; Williams Lawrence E; Liu An; Zhan Jiping; Yamauchi Dave M; Wilczynski Sharon; Wu Anna M; Yazaki Paul J; Shively John E; Leong Lucille; Raubitschek Andrew A
A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
Cancer biotherapy & radiopharmaceuticals 2006;21(2):88-100.
2006: Li Lin; Yazaki Paul J; Anderson Anne-Line; Crow Desiree; Colcher David; Wu Anna M; Williams Lawrence E; Wong Jeffrey Y C; Raubitschek Andrew; Shively John E
Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.
Bioconjugate chemistry 2006;17(1):68-76.
2005: Nademanee Auayporn; Forman Stephen; Molina Arturo; Fung Henry; Smith David; Dagis Andy; Kwok Cheuk; Yamauchi Dave; Anderson Anne-Line; Falk Peter; Krishnan Amrita; Kirschbaum Mark; Kogut Neil; Nakamura Ryotaro; O'donnell Margaret; Parker Pablo; Popplewell Leslie; Pullarkat Vinod; Rodriguez Roberto; Sahebi Firoozeh; Smith Eileen; Snyder David; Stein Anthony; Spielberger Ricardo; Zain Jasmine; White Christine; Raubitschek Andrew
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Blood 2005;106(8):2896-902.
2005: Crow Desiree M; Williams Lawrence; Colcher David; Wong Jeffrey Y C; Raubitschek Andrew; Shively John E
Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Bioconjugate chemistry 2005;16(5):1117-25.
2005: Schnell Roland; Dietlein Markus; Staak Jan Oliver; Borchmann Peter; Schomaecker Klaus; Fischer Thomas; Eschner Wolfgang; Hansen Hinrich; Morschhauser Franck; Schicha Harald; Diehl Volker; Raubitschek Andrew; Engert Andreas
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(21):4669-78.
2005: Olafsen Tove; Kenanova Vania E; Sundaresan Gobalakrishnan; Anderson Anne-Line; Crow Desiree; Yazaki Paul J; Li Lin; Press Michael F; Gambhir Sanjiv S; Williams Lawrence E; Wong Jeffrey Y C; Raubitschek Andrew A; Shively John E; Wu Anna M
Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
Cancer research 2005;65(13):5907-16.
2005: Nagata Satoshi; Ise Tomoko; Onda Masanori; Nakamura Kazuyasu; Ho Mitchell; Raubitschek Andrew; Pastan Ira H
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(22):7946-51.
2005: Gillies Stephen D; Lan Yan; Williams Steven; Carr Frank; Forman Stephen; Raubitschek Andrew; Lo Kin-Ming
An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
Blood 2005;105(10):3972-8.
2005: Hockaday David C; Shen Sui; Fiveash John; Raubitschek Andrew; Colcher David; Liu An; Alvarez Vern; Mamelak Adam N
Imaging glioma extent with 131I-TM-601.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(4):580-6.
2005: Brown Christine E; Wright Christine L; Naranjo Araceli; Vishwanath Reena P; Chang Wen-Chung; Olivares Simon; Wagner Jamie R; Bruins Laura; Raubitschek Andrew; Cooper Laurence J N; Jensen Michael C
Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing.
Journal of immunological methods 2005;297(1-2):39-52.
2005: Kenanova Vania; Olafsen Tove; Crow Desiree M; Sundaresan Gobalakrishnan; Subbarayan Murugesan; Carter Nora H; Ikle David N; Yazaki Paul J; Chatziioannou Arion F; Gambhir Sanjiv S; Williams Lawrence E; Shively John E; Colcher David; Raubitschek Andrew A; Wu Anna M
Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Cancer research 2005;65(2):622-31.
2005: Cooper Laurence J N; Kalos Michael; DiGiusto David; Brown Christine; Forman Stephen J; Raubitschek Andrew; Jensen Michael C
T-cell genetic modification for re-directed tumor recognition.
Cancer chemotherapy and biological response modifiers 2005;22():293-324.
2004: Kahlon Kanwarpal S; Brown Christine; Cooper Laurence J N; Raubitschek Andrew; Forman Stephen J; Jensen Michael C
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Cancer research 2004;64(24):9160-6.
2004: Wong Jeffrey Y C; Chu David Z; Williams Lawrence E; Yamauchi Dave M; Ikle David N; Kwok Cheuk S; Liu An; Wilczynski Sharon; Colcher David; Yazaki Paul J; Shively John E; Wu Anna M; Raubitschek Andrew A
Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5014-21.
2004: Cooper Laurence J N; Al-Kadhimi Zaid; DiGiusto David; Kalos Michael; Colcher David; Raubitschek Andrew; Forman Steve J; Jensen Michael C
Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.
Blood cells, molecules & diseases 2004;33(1):83-9.
2004: Yazaki Paul J; Sherman Mark A; Shively John E; Ikle David; Williams Lawrence E; Wong Jeffrey Y C; Colcher David; Wu Anna M; Raubitschek Andrew A
Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
Protein engineering, design & selection : PEDS 2004;17(5):481-9.
2004: Olafsen Tove; Tan Giselle J; Cheung Chia-Wei; Yazaki Paul J; Park Jinha M; Shively John E; Williams Lawrence E; Raubitschek Andrew A; Press Michael F; Wu Anna M
Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.
Protein engineering, design & selection : PEDS 2004;17(4):315-23.
2004: Wang Jinjuan; Press Oliver W; Lindgren Catherine G; Greenberg Philip; Riddell Stanley; Qian Xiaojun; Laugen Christian; Raubitschek Andrew; Forman Stephen J; Jensen Michael C
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(4):577-86.
2004: Olafsen Tove; Cheung Chia-Wei; Yazaki Paul J; Li Lin; Sundaresan Gobalakrishnan; Gambhir Sanjiv S; Sherman Mark A; Williams Lawrence E; Shively John E; Raubitschek Andrew A; Wu Anna M
Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.
Protein engineering, design & selection : PEDS 2004;17(1):21-7.
2003: Wong Jeffrey Y C; Shibata Stephen; Williams Lawrence E; Kwok Cheuk S; Liu An; Chu David Z; Yamauchi Dave M; Wilczynski Sharon; Ikle David N; Wu Anna M; Yazaki Paul J; Shively John E; Doroshow James H; Raubitschek Andrew A
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5842-52.
2003: Sundaresan Gobalakrishnan; Yazaki Paul J; Shively John E; Finn Ronald D; Larson Steven M; Raubitschek Andrew A; Williams Lawrence E; Chatziioannou Arion F; Gambhir Sanjiv S; Wu Anna M
124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(12):1962-9.
2003: Cooper Laurence J N; Topp Max S; Serrano Lisa Marie; Gonzalez Sergio; Chang Wen-Chung; Naranjo Araceli; Wright Christine; Popplewell Leslie; Raubitschek Andrew; Forman Stephen J; Jensen Michael C
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
Blood 2003;101(4):1637-44.
2003: Jensen M C; Cooper L J N; Wu A M; Forman S J; Raubitschek A
Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
Cytotherapy 2003;5(2):131-8.
2002: Li Lin; Olafsen Tove; Anderson Anne-Line; Wu Anna; Raubitschek Andrew A; Shively John E
Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody.
Bioconjugate chemistry 2002;13(5):985-95.
2002: Williams Lawrence E; Liu An; Yamauchi Dave M; Lopatin George; Raubitschek Andrew A; Wong Jeffrey Y C
The two types of correction of absorbed dose estimates for internal emitters.
Cancer 2002;94(4 Suppl):1231-4.
2002: Li Lin; Tsai Shih-Wa; Anderson Anne-Line; Keire David A; Raubitschek Andrew A; Shively John E
Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistributions.
Bioconjugate chemistry 2002;13(1):110-5.
2001: Wu A M; Tan G J; Sherman M A; Clarke P; Olafsen T; Forman S J; Raubitschek A A
Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange.
Protein engineering 2001;14(12):1025-33.
2001: Yazaki P J; Shively L; Clark C; Cheung C W; Le W; Szpikowska B; Shively J E; Raubitschek A A; Wu A M
Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.
Journal of immunological methods 2001;253(1-2):195-208.
2001: Lewis M R; Kao J Y; Anderson A L; Shively J E; Raubitschek A
An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.
Bioconjugate chemistry 2001;12(2):320-4.
2001: Tsai S W; Li L; Williams L E; Anderson A L; Raubitschek A A; Shively J E
Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.
Bioconjugate chemistry 2001;12(2):264-70.
2001: Yazaki P J; Wu A M; Tsai S W; Williams L E; Ikler D N; Wong J Y; Shively J E; Raubitschek A A
Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
Bioconjugate chemistry 2001;12(2):220-8.
2001: Williams L E; Wu A M; Yazaki P J; Liu A; Raubitschek A A; Shively J E; Wong J Y
Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Cancer biotherapy & radiopharmaceuticals 2001;16(1):25-35.
2000: Wong JYC; Chu D Z; Yamauchi D M; Williams L E; Liu A; Wilczynski S; Wu A M; Shively J E; Doroshow J H; Raubitschek A A
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3855-63.
2000: Wu A M; Yazaki P J; Tsai S w; Nguyen K; Anderson A L; McCarthy D W; Welch M J; Shively J E; Williams L E; Raubitschek A A; Wong J Y; Toyokuni T; Phelps M E; Gambhir S S
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(15):8495-500.
2000: Williams L E; Liu A; Wu A M; Yazaki P J; Yamauchi D M; Lopatin G; Raubitschek A A; Wong J Y
Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.
Medical physics 2000;27(5):988-94.
2000: Tsai S W; Sun Y; Williams L E; Raubitschek A A; Wu A M; Shively J E
Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
Bioconjugate chemistry 2000;11(3):327-34.
2000: Wong J Y; Wang J; Liu A; Odom-Maryon T; Shively J E; Raubitschek A A; Williams L E
Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.
International journal of radiation oncology, biology, physics 2000;46(3):599-607.
2000: Jensen M C; Clarke P; Tan G; Wright C; Chung-Chang W; Clark T N; Zhang F; Slovak M L; Wu A M; Forman S J; Raubitschek A
Human T lymphocyte genetic modification with naked DNA.
Molecular therapy : the journal of the American Society of Gene Therapy 2000;1(1):49-55.
1999: Wong J Y; Somlo G; Odom-Maryon T; Williams L E; Liu A; Yamauchi D; Wu A M; Yazaki P; Wilczynski S; Shively J E; Forman S; Doroshow J H; Raubitschek A A
Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3224s-3231s.
1999: Williams L E; Liu A; Raubitschek A A; Wong J Y
A method for patient-specific absorbed dose estimation for internal beta emitters.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3015s-3019s.
1999: Liu A; Williams L E; Lopatin G; Yamauchi D M; Wong J Y; Raubitschek A A
A radionuclide therapy treatment planning and dose estimation system.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(7):1151-3.
1999: Clarke K G; Odom-Maryon T L; Williams L E; Liu A; Lopatin G; Chou J; Farino G M; Raubitschek A A; Wong J Y
Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy.
Medical physics 1999;26(5):799-809.
1999: Carrasquillo J A; White J D; Paik C H; Raubitschek A; Le N; Rotman M; Brechbiel M W; Gansow O A; Top L E; Perentesis P; Reynolds J C; Nelson D L; Waldmann T A
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(2):268-76.
1998: Wong J Y; Chu D Z; Yamauchi D; Odom-Maryon T L; Williams L E; Liu A; Esteban J M; Wu A M; Primus F J; Beatty J D; Shively J E; Raubitschek A A
Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(12):2097-104.
1998: Liu A; Williams L E; Wong J Y; Raubitschek A A
Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry.
Nuclear medicine and biology 1998;25(4):423-33.
1998: Williams L E; Lewis M R; Bebb G G; Clarke K G; Odom-Maryon T L; Shively J E; Raubitschek A A
Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
Bioconjugate chemistry 1998;9(1):87-93.
1998: Jensen M; Tan G; Forman S; Wu A M; Raubitschek A
CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1998;4(2):75-83.
1997: Kaplan D D; Williams L E; Clarke K G; Odom-Maryon T L; Liu A; Lopatin G; Raubitschek A A; Wong J Y
Estimating residence times and their associated errors in patient absorbed-dose calculation.
Journal of nuclear medicine technology 1997;25(4):264-8.
1997: Odom-Maryon T L; Williams L E; Chai A; Lopatin G; Liu A; Wong Y C; Chou J; Clarke K G; Raubitschek A A
Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(12):1959-66.
1997: Wong J Y; Thomas G E; Yamauchi D; Williams L E; Odom-Maryon T L; Liu A; Esteban J M; Neumaier M; Dresse S; Wu A M; Primus F J; Shively J E; Raubitschek A A
Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(12):1951-9.
1996: Hu S; Shively L; Raubitschek A; Sherman M; Williams L E; Wong J Y; Shively J E; Wu A M
Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
Cancer research 1996;56(13):3055-61.
1996: Wu A M; Chen W; Raubitschek A; Williams L E; Neumaier M; Fischer R; Hu S Z; Odom-Maryon T; Wong J Y; Shively J E
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.
Immunotechnology : an international journal of immunological engineering 1996;2(1):21-36.
1995: Williams L E; Liu A; Wu A M; Odom-Maryon T; Chai A; Raubitschek A A; Wong J Y
Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies.
Medical physics 1995;22(12):2025-7.
1995: Williams L E; Odom-Maryon T L; Liu A; Chai A; Raubitschek A A; Wong J Y; D'Argenio D Z
On the correction for radioactive decay in pharmacokinetic modeling.
Medical physics 1995;22(10):1619-26.
1995: Thomas G E; Esteban J M; Raubitschek A; Wong J Y
gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
International journal of radiation oncology, biology, physics 1995;31(3):529-34.
1994: Lewis M R; Raubitschek A; Shively J E
A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate stability in radiolabeled immunoconjugates.
Bioconjugate chemistry 1994;5(6):565-76.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Andrew Raubitschek

Research Profile (preview)

Chemicals & Drugs

Living Beings

Procedures

Concepts & Ideas

Anatomy

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Andrew Raubitschek (preview)

All Publications